Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2025 Oct 1:436:133422.
doi: 10.1016/j.ijcard.2025.133422. Epub 2025 May 25.

Contemporary management of acute pulmonary embolism

Affiliations
Review

Contemporary management of acute pulmonary embolism

Gianluca Guarnieri et al. Int J Cardiol. .

Abstract

Acute pulmonary embolism (PE) is one of the leading causes of in-hospital mortality and the third more frequent cause of cardiovascular mortality. The optimal management of PE patients is a clinical conundrum since the spectrum of PE manifestations varies largely depending on clinical and hemodynamic features. According to international guidelines, systemic thrombolysis ranks as first-line treatment for high-risk PE complicated by hemodynamic instability. However, a not negligible proportion of PE patients present contraindications to systemic thrombolysis. Among hemodynamically stable patients with right ventricular dysfunction ("intermediate risk" PE), anticoagulation alone remains the standard treatment but is still associated with relevant risk. Novel interventional techniques including catheter-directed thrombolysis, mechanical thrombectomy, and hybrid approaches have been developed to facilitate reperfusion while mitigating the risk of bleeding. In this review, we provide a comprehensive and contemporary overview of pharmacological and interventional treatments for PE, moving from clinical evidence to practical recommendations and future directions.

Keywords: Catheter-directed thrombolysis; Mechanical thrombectomy; Pulmonary embolism; Thrombolysis.

PubMed Disclaimer

Conflict of interest statement

Declaration of competing interest A.L. reports personal fees from Terumo. S.B. reports institutional grants from Boston Scientific and Concept Medical, honoraria from Boston Scientific, INARI, Penumbra, Concept Medical. M.V. reports grants and/or personal fees from Astra Zeneca, Terumo, Alvimedica/CID, Abbott Vascular, Daiichi Sankyo, Bayer, CoreFLOW, Idorsia Pharmaceuticals-Ltd, Universität Basel Department Klinische Forschung, Vifor, Bristol-Myers-Squib SA, Biotronik, Boston scientific, Medtronic, Vesalio, Novartis, Chiesi, PhaseBio, outside the submitted work. The other authors report no relationships relevant to the contents of this paper to disclose.

LinkOut - more resources